伊曲康唑治疗侵袭性真菌性鼻窦炎：SECURE 和 VITAL 试验的事后分析。

Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.

机构信息

Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.

Astellas Pharma Global Development, Northbrook, Illinois, USA.

出版信息

Clin Infect Dis. 2021 Sep 15;73(6):e1380-e1383. doi: 10.1093/cid/ciab386.

DOI:10.1093/cid/ciab386

PMID:33914864

Abstract

This post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) therapy for a median of 82 days (range, 2-882). Overall survival was 82% at day 42 and 70% at day 84.

摘要

本事后分析了国际 III 期临床试验，共纳入 50 例侵袭性真菌性鼻窦炎患者（90%为免疫功能低下或糖尿病患者），这些患者接受伊曲康唑作为一线（n=33）或挽救性（n=17）治疗，中位治疗时间为 82 天（范围：2-882 天）。第 42 天和第 84 天的总体生存率分别为 82%和 70%。